- Trials with a EudraCT protocol (3,632)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3,632 result(s) found for: oncology.
Displaying page 7 of 182.
| EudraCT Number: 2004-003910-41 | Sponsor Protocol Number: 1527-852A | Start Date*: 2005-04-28 |
| Sponsor Name:3M Health Care Limited | ||
| Full Title: Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects with Unresectable Metastatic Cutaneous Melanoma | ||
| Medical condition: Unresectable metastatic cutaneous melanoma Stage III (local and regional metastasis) and Stage IV | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-005218-35 | Sponsor Protocol Number: NSGO-CC-0301 | Start Date*: 2006-05-18 |
| Sponsor Name:Nordic Society of Gynecological Oncology (NSGO) | ||
| Full Title: A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma | ||
| Medical condition: Locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000370-19 | Sponsor Protocol Number: CO-1686-022 | Start Date*: 2015-01-14 | |||||||||||
| Sponsor Name:Clovis Oncology, Inc. | |||||||||||||
| Full Title: TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
| Medical condition: First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-004350-28 | Sponsor Protocol Number: VEG20007 | Start Date*: 2006-08-22 |
| Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
| Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or... | ||
| Medical condition: Advanced or metastatic breast cancer with ErbB2 FISH postive tumours | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: GB (Completed) HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-002150-64 | Sponsor Protocol Number: MCL 03 | Start Date*: 2004-12-22 |
| Sponsor Name:Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology | ||
| Full Title: Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma | ||
| Medical condition: relapsed mantle cell lymphoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000364-30 | Sponsor Protocol Number: I4T-MC-JVDA | Start Date*: 2021-06-01 |
| Sponsor Name:Eli Lilly and Company | ||
| Full Title: A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors | ||
| Medical condition: Pediatric Solid Tumor CNS Malignancies | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2004-005164-25 | Sponsor Protocol Number: 04.09 | Start Date*: 2005-04-14 |
| Sponsor Name:Odense University Hospital | ||
| Full Title: Phase II study of thalidomide in combination with temozolomide in metastatic malignant melanoma with brain metastases | ||
| Medical condition: Advanced metastic malignant melanoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004486-86 | Sponsor Protocol Number: SRA737-01 | Start Date*: 2016-04-25 | |||||||||||
| Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
| Full Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer | |||||||||||||
| Medical condition: Patients with histologically or cytologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003230-15 | Sponsor Protocol Number: BEV-EFF | Start Date*: 2006-10-17 |
| Sponsor Name:University Clinic Internal Medicine I | ||
| Full Title: Phase I/II study investigating increasing doses of bevacizumab in patients with malignant effusion | ||
| Medical condition: Malignant effusion in cancer patients requiring frequent centesis, at least two within six weeks | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-001248-23 | Sponsor Protocol Number: 12-CCEE | Start Date*: 2014-07-02 | ||||||||||||||||||||||||||
| Sponsor Name:All Ireland Cooperative Oncology Research Group | ||||||||||||||||||||||||||||
| Full Title: Treatment of Inoperable Colorectal Cancer with Electrochemotherapy through an Endoscopic System | ||||||||||||||||||||||||||||
| Medical condition: Colorectal cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2016-005225-37 | Sponsor Protocol Number: 16-12301 | Start Date*: 2018-08-10 |
| Sponsor Name:Sahlgrenska University Hospital | ||
| Full Title: The ASTEROID trial - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patien... | ||
| Medical condition: Stage I Non-small cell lung cancer (NSCLC) that has been treated with Stereotactic Body Radiotherapy (SBRT). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-005990-29 | Sponsor Protocol Number: ENGOT-OV64/NSGO-CTU-SOLERO | Start Date*: 2021-12-14 | |||||||||||||||||||||
| Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU) | |||||||||||||||||||||||
| Full Title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer | |||||||||||||||||||||||
| Medical condition: Patients with histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer with radiologically or histologically confirmation of relapsed disease, and with known BRCA wi... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) NO (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-000945-15 | Sponsor Protocol Number: TAS-120-203 | Start Date*: 2021-07-28 | ||||||||||||||||
| Sponsor Name:Taiho Oncology, Inc. | ||||||||||||||||||
| Full Title: A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma | ||||||||||||||||||
| Medical condition: Advanced or Metastatic Urothelial Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-000142-34 | Sponsor Protocol Number: ITCC-092/IST11028 | Start Date*: 2020-09-15 | ||||||||||||||||
| Sponsor Name:Princess Máxima Center for pediatric oncology | ||||||||||||||||||
| Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092 | ||||||||||||||||||
| Medical condition: Relapsed or refractory pediatric acute myeloid leukemia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-001071-37 | Sponsor Protocol Number: LUC19-001 | Start Date*: 2019-08-06 |
| Sponsor Name:Cliniques Universitaires Saint-Luc | ||
| Full Title: Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido | ||
| Medical condition: Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003187-32 | Sponsor Protocol Number: etoxel-01-2005 | Start Date*: 2005-12-19 |
| Sponsor Name:Department of Oncology, Rigshospitalet | ||
| Full Title: A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinoma | ||
| Medical condition: Advanced Hepatocellular carcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000705-25 | Sponsor Protocol Number: AT148002 | Start Date*: 2021-06-09 | |||||||||||
| Sponsor Name:ALX Oncology Inc. | |||||||||||||
| Full Title: A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02) | |||||||||||||
| Medical condition: Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-012260-14 | Sponsor Protocol Number: 20050418 | Start Date*: 2010-08-27 |
| Sponsor Name:Department of Endocrine Oncology | ||
| Full Title: An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors | ||
| Medical condition: Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004939-22 | Sponsor Protocol Number: HE 5/06 | Start Date*: 2006-05-02 |
| Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG) | ||
| Full Title: A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCER | ||
| Medical condition: Recurrent or metastatic non-nasopharyngeal head and neck cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003074-27 | Sponsor Protocol Number: SMS-0472B | Start Date*: 2018-11-30 |
| Sponsor Name:WntResearch | ||
| Full Title: A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer. | ||
| Medical condition: Subjects with resectable adenocarcinoma of the colon and who, at the time of screening, are considered to fulfil the local criteria for adjuvant post-operative chemotherapy. Based on CT/MRI subject... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Temporarily Halted) NL (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
